LEGN250117P52500
- 0.00
- 0.000.00%
Legend Biotech Newsroom
Jefferies Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $91
Goldman Sachs Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $84.28
BMO Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $90
Legend Biotech Analyst Ratings
H.C. Wainwright Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $73
Legend Biotech: Strong Buy Rating Driven by Competitive Positioning of CARVYKTI Amidst Safety and Regulatory Confidence
RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $84
BMO Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $90
Promising Growth Trajectory and Market Expansion Justify Buy Rating for Legend Biotech
RBC Trims Price Target on Legend Biotech to $84 From $86, Keeps Outperform Rating
Legend Biotech Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN) and NewAmsterdam Pharma Company (NAMS)
Piper Sandler Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $78
BMO Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $90
A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $65 to $91
HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $73 Price Target
Optimistic Buy Rating for Legend Biotech Driven by Carvykti's Success and Growth Potential
William Blair Sticks to Its Hold Rating for Legend Biotech (LEGN)
Legend Biotech Analyst Ratings
RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $86